```
is in DialUnits
? b 410
       01jul10 12:29:18 User208760 Session D3196.1
            $0.57    0.152 DialUnits File1
     $0.57  Estimated cost File1
     $0.02  TELNET
     $0.59  Estimated cost this search
     $0.59  Estimated total session cost   0.152 DialUnits

File 410:The Chronolog 1991-2010/ Mar
       (c) 2010 Dialog. All rights reserved.

      Set  Items  Description
      ---  -----  -----------
? set hi ;set hi
HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,73,155,399
       01jul10 12:29:25 User208760 Session D3196.2
            $0.00    0.115 DialUnits File410
     $0.00  Estimated cost File410
     $0.03  TELNET
     $0.03  Estimated cost this search
     $0.62  Estimated total session cost   0.267 DialUnits

SYSTEM:OS  - DIALOG OneSearch
  File   5:Biosis Previews(R) 1926-2010/Jun W4
         (c) 2010 The Thomson Corporation
  File  73:EMBASE 1974-2010/Jul 01
         (c) 2010 Elsevier B.V.
*File  73: The archive of Medline derived records was added to Embase.
  File 155:MEDLINE(R) 1950-2010/Jun 29
         (c) format only 2010 Dialog
*File 155: Medline has been reloaded. Please see HELP NEWS154
for information.
  File 399:CA SEARCH(R) 1967-2010/UD=15301
         (c) 2010 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

      Set  Items  Description
      ---  -----  -----------
? e au=tedesco francesco ?

Ref   Items  Index-term
E1        4  AU=TEDESCO F.S.
E2      101  AU=TEDESCO FRANCESCO
E3        0 *AU=TEDESCO FRANCESCO ?
E4        6  AU=TEDESCO FRANCESCO SAVERIO
E5       32  AU=TEDESCO G
E6       28  AU=TEDESCO G.
E7        2  AU=TEDESCO G.D.
E8        1  AU=TEDESCO GIANNI
E9        1  AU=TEDESCO GIOACCHINO
E10      31  AU=TEDESCO GIOVANNA
E11       2  AU=TEDESCO GISELLE DAHAREM
E12       4  AU=TEDESCO GISELLE DARAHEM

          Enter P or PAGE for more
? s e1-e4
               4  AU=TEDESCO F.S.
```

```
             101  AU=TEDESCO FRANCESCO
               0  AU=TEDESCO FRANCESCO ?
               6  AU=TEDESCO FRANCESCO SAVERIO
      S1     111  E1-E4
? e au=marzari roberto ?

Ref   Items  Index-term
E1       63  AU=MARZARI R.
E2       72  AU=MARZARI ROBERTO
E3        0 *AU=MARZARI ROBERTO ?
E4        3  AU=MARZARI VICTOR
E5        1  AU=MARZARI-CHIESA A
E6        1  AU=MARZARI-CHIESA A.
E7       95  AU=MARZARI-CHIESA, A.
E8        3  AU=MARZARI-CHIESA, ALBERTA
E9        3  AU=MARZARI, A.
E10       1  AU=MARZARI, C.
E11       1  AU=MARZARI, CHIARA
E12       1  AU=MARZARI, CHRISTIAN M.

          Enter P or PAGE for more
? s e1-e2
              63  AU=MARZARI R.
              72  AU=MARZARI ROBERTO
      S2     135  E1-E2
? s (s1 or s2) and (antibod? or immunoglobulin? or hybridoma?)(20n)(c5a or
ts(w)a12?)
             111  S1
             135  S2
         2724863  ANTIBOD?
         1064219  IMMUNOGLOBULIN?
           61953  HYBRIDOMA?
           14523  C5A
           50236  TS
            5903  A12?
               4  TS(W)A12?
            1785  ((ANTIBOD? OR IMMUNOGLOBULIN?) OR HYBRIDOMA?)(20N)(C5A OR
                  TS(W)A12?)
      S3       5  (S1 OR S2) AND (ANTIBOD? OR IMMUNOGLOBULIN? OR
                  HYBRIDOMA?)(20N)(C5A OR TS(W)A12?)
? rd s3
      S4       2  RD S3  (unique items)
? t s4/3/all

 4/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

16983076   BIOSIS NO.: 200200576587
The cleavage site of C5 from man and animals as a common target for
  neutralizing human monoclonal antibodies: In vitro and in vivo studies
AUTHOR: Marzari Roberto; Sblattero Daniele; Macor Paolo; Fischetti
  Fabio; Gennaro Renato; Marks James D; Bradbury Andrew; Tedesco
  Francesco (Reprint)
AUTHOR ADDRESS: Dipartimento di Fisiologia e Patologia, Universita di
  Trieste, Via Fleming 22, I-34127, Trieste, Italy**Italy
JOURNAL: European Journal of Immunology  32 (10): p2773-2782 October, 2002
2002
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
```

RECORD TYPE: Abstract
LANGUAGE: English

4/3/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2010 Elsevier B.V. All rts. reserv.

0081757282 EMBASE/Medline No: 2007191236
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats
Fischetti F.; Durigutto P.; Macor P.; ***Marzari R.*** ; Carretta R.; Tedesco F.
University of Trieste, Trieste, Italy
AUTHOR EMAIL: tedesco@units.it
CORRESP. AUTHOR/AFFIL: Tedesco F.: Department of Physiology and Pathology, University of Trieste, via Valerio 28, 34127 Trieste, Italy
CORRESP. AUTHOR EMAIL: tedesco@units.it

Arthritis and Rheumatism ( Arthritis Rheum. ) (United States) April 1, 2007, 56/4 (1187-1197)
CODEN: ARHEA ISSN: 0004-3591
DOI: 10.1002/art.22492
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 56
? t s4/7/all

4/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

16983076 BIOSIS NO.: 200200576587
The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: In vitro and in vivo studies
AUTHOR: Marzari Roberto; Sblattero Daniele; Macor Paolo; Fischetti Fabio; Gennaro Renato; Marks James D; Bradbury Andrew; Tedesco Francesco (Reprint)
AUTHOR ADDRESS: Dipartimento di Fisiologia e Patologia, Universita di Trieste, Via Fleming 22, I-34127, Trieste, Italy**Italy
JOURNAL: European Journal of Immunology 32 (10): p2773-2782 October, 2002 2002
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The isolation of an anti-C5 single-chain fragment variable (scFv) antibody, TS-A12/22, from a human phage display library, is described. This ***antibody*** inhibits the activation of C5 and the assembly of the terminal complement complex implicated in cell and tissue damage. Using ***antibody*** -sensitized sheep erythrocytes and rabbit red cells as target cells in hemolytic assays, we found that TS-A12/22 inhibited the activation of C5 by the convertases of both classical and alternative pathways. Western blot analysis and competition experiments with synthetic peptides showed that TS-A12/22 reacted with the a chain of C5 and recognized the cleavage site of this complement component by the C5 convertase. As a result, the ***antibody*** prevented splitting of C5 and inhibited the generation of C5a and of the

terminal complement complex. The identification of the ***TS*** - ***A12*** /22 recognition site as a conserved sequence in man, mouse, rat and rabbit enabled the demonstration of in vitro inhibition of complement activity in these species. The scFv TS-A12/22 was tested in a rat model of antigen-induced arthritis and proved to be effective in preventing influx of polymorphonuclear cells into the knee joint and C9 deposition on synovial tissue.

4/7/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2010 Elsevier B.V. All rts. reserv.

0081757282 EMBASE/Medline No: 2007191236
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats
Fischetti F.; Durigutto P.; Macor P.; ***Marzari R.*** ; Carretta R.; Tedesco F.
University of Trieste, Trieste, Italy
AUTHOR EMAIL: tedesco@units.it
CORRESP. AUTHOR/AFFIL: Tedesco F.: Department of Physiology and Pathology, University of Trieste, via Valerio 28, 34127 Trieste, Italy
CORRESP. AUTHOR EMAIL: tedesco@units.it

Arthritis and Rheumatism ( Arthritis Rheum. ) (United States) April 1, 2007, 56/4 (1187-1197)
CODEN: ARHEA ISSN: 0004-3591
DOI: 10.1002/art.22492
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 56

Objective. To determine the role of the terminal complement complex (TCC) in the development of experimental antigen-induced arthritis (AIA) and the therapeutic effects of human anti-C5 single-chain Fv (scFv). Methods. Two different anti-C5 scFv, one that inhibits both release of C5a and assembly of the TCC (TS-A 12/22) and another that selectively blocks formation of the TCC (TS-A 8), were injected at the onset of AIA. The effects of these scFv on disease severity were evaluated for up to 21 days and compared with the effects of injection of an unrelated scFv. AIA was also established in C6-deficient and C6-sufficient PVG rats to obtain further information on the role of the TCC in this model. Results. TS-A 12/22 and TS-A 8 proved to be equally effective in reducing joint swelling, cell counts and tumor necrosis factor alpha levels in synovial lavage fluids, and the degree of histomorphologic changes compared with the effects of the unrelated scFv. TS-A 12/22 and TS-A 8 prevented the deposition of C9 but not that of C3, confirming the ability of the 2 scFv to neutralize C5. Administration of the 2 anti-C5 scFv after AIA onset also reduced disease severity. In C6-deficient rats with AIA, disease activity was reduced markedly compared with that in C6-sufficient rats. Conclusion. These 2 human anti-C5 scFv could represent potential therapeutic reagents to be used in patients with rheumatoid arthritis. In addition, the finding that TS-A 8 was as effective as TS-A 12/22 in reducing disease severity suggests that the TCC is mainly responsible for the joint inflammation and damage observed in AIA. (c) 2007, American College of Rheumatology.
? s (antibod? or immunoglobulin? or hybridoma?)(20n)(c5a or ts(w)a12?)
2724863 ANTIBOD?
1064219 IMMUNOGLOBULIN?
61953 HYBRIDOMA?
14523 C5A

```
           50236  TS
            5903  A12?
               4  TS(W)A12?
      S5    1785  (ANTIBOD? OR IMMUNOGLOBULIN? OR HYBRIDOMA?)(20N)(C5A OR
                  TS(W)A12?)
? s (antibod? or immunoglobulin? or hybridoma?)(20n)(c5a)same(ts(w)a12?)
         2724863  ANTIBOD?
         1064219  IMMUNOGLOBULIN?
           61953  HYBRIDOMA?
               0  C5A)SAME(TS
               0  A12?)
      S6       0  (ANTIBOD? OR IMMUNOGLOBULIN? OR
                  HYBRIDOMA?)(20N)(C5A)SAME(TS(W)A12?)
? s (antibod? or immunoglobulin? or hybridoma?)(20n)(c5a) and (ts(w)a12?)
         2724863  ANTIBOD?
         1064219  IMMUNOGLOBULIN?
           61953  HYBRIDOMA?
           14523  C5A
            1785  ((ANTIBOD? OR IMMUNOGLOBULIN?) OR HYBRIDOMA?)(20N)C5A
           50236  TS
            5903  A12?
               4  TS(W)A12?
      S7       4  (ANTIBOD? OR IMMUNOGLOBULIN? OR HYBRIDOMA?)(20N)(C5A) AND
                  (TS(W)A12?)
? rd s7
      S8       2  RD S7  (unique items)
? t s8/3/all

 8/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

16983076   BIOSIS NO.: 200200576587
The cleavage site of C5 from man and animals as a common target for
  neutralizing human monoclonal antibodies: In vitro and in vivo studies
AUTHOR: Marzari Roberto; Sblattero Daniele; Macor Paolo; Fischetti Fabio;
  Gennaro Renato; Marks James D; Bradbury Andrew; Tedesco Francesco
  (Reprint)
AUTHOR ADDRESS: Dipartimento di Fisiologia e Patologia, Universita di
  Trieste, Via Fleming 22, I-34127, Trieste, Italy**Italy
JOURNAL: European Journal of Immunology  32 (10): p2773-2782 October, 2002
2002
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English


 8/3/2     (Item 1 from file: 73)
DIALOG(R)File  73:EMBASE
(c) 2010 Elsevier B.V. All rts. reserv.

0082118885     EMBASE/Medline No: 2007532089
  Rheumatoid arthritis and the complement system
  Okroj M.; Heinegard D.; Holmdahl R.; Blom A.M.
  Lund University, Department of Laboratory Medicine, University Hospital
  Malmo, Malmo, Sweden
  AUTHOR EMAIL: Anna.Blom@med.lu.se
  CORRESP. AUTHOR/AFFIL: Blom A.M.: Lund University, Department of
Laboratory Medicine, University Hospital Malmo, Entrance 46, S-205 02 Malmo
```

, Sweden
  CORRESP. AUTHOR EMAIL: Anna.Blom@med.lu.se

  Annals of Medicine ( Ann. Med. ) (Norway)  November 15, 2007, 39/7
  (517-530)
  CODEN: ANMDE   ISSN: 0785-3890  eISSN: 1651-2219
  PUBLISHER ITEM IDENTIFIER: 780337113
  DOI: 10.1080/07853890701477546
  DOCUMENT TYPE: Journal; Review  RECORD TYPE: Abstract
  LANGUAGE: English   SUMMARY LANGUAGE: English
  NUMBER OF REFERENCES: 139
? s (antibod? or immunoglobulin? or hybridoma?)(20n)(c5a)(20n)(cleavage(w)site)
         2724863  ANTIBOD?
         1064219  IMMUNOGLOBULIN?
           61953  HYBRIDOMA?
           14523  C5A
          390866  CLEAVAGE
         1961132  SITE
      S9       3  (ANTIBOD? OR IMMUNOGLOBULIN? OR
                  HYBRIDOMA?)(20N)(C5A)(20N)(CLEAVAGE(W)SITE)
? rd s9
     S10       1  RD S9  (unique items)
? t s10/3/all

 10/3/1     (Item 1 from file: 5)
DIALOG(R)File   5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

16983076   BIOSIS NO.: 200200576587
The cleavage site of C5 from man and animals as a common target for
  neutralizing human monoclonal antibodies: In vitro and in vivo studies
AUTHOR: Marzari Roberto; Sblattero Daniele; Macor Paolo; Fischetti Fabio;
  Gennaro Renato; Marks James D; Bradbury Andrew; Tedesco Francesco
  (Reprint)
AUTHOR ADDRESS: Dipartimento di Fisiologia e Patologia, Universita di
  Trieste, Via Fleming 22, I-34127, Trieste, Italy**Italy
JOURNAL: European Journal of Immunology  32 (10): p2773-2782 October, 2002
2002
MEDIUM: print
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
?